Gary M. Clark
No más puestos en curso
Historial de carrera de Gary M. Clark
Antiguos cargos conocidos de Gary M. Clark.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| Cancer Therapy & Research Center Endowment | Corporate Officer/Principal | - | - |
Flagship Biosciences, Inc.
 Flagship Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Flagship Biosciences, Inc. engages in medical and biological research. It offers drug development support, including target validation and hypothesis generation, exploratory and efficacy endpoints, predictive strategy building and companion diagnostics.The company was founded by G. David Young in 2009 and is headquartered in Broomfield, CO. | Director/Miembro de la Junta | - | - |
| University of Kansas | Corporate Officer/Principal | - | - |
| University of Texas Health Center | Corporate Officer/Principal | - | - |
| Baylor College of Medicine | Corporate Officer/Principal | - | - |
| OSI PHARMACEUTICALS, INC. | Corporate Officer/Principal | - | - |
| ARRAY TECHNOLOGIES, INC. | Corporate Officer/Principal | 18/03/2008 | - |
Formación de Gary M. Clark.
| University of Washington | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 9 |
Operativa
| Corporate Officer/Principal | 6 |
| Doctorate Degree | 1 |
| Graduate Degree | 1 |
Sectorial
| Consumer Services | 5 |
| Health Technology | 3 |
| Health Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas privadas | 4 |
|---|---|
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
OSI Pharmaceuticals, Inc.
 OSI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OSI Pharmaceuticals, Inc. manufactured and develope dpharmaceutical drugs. The company was founded in 1983 and was headquartered in Farmingdale, NY. | Health Technology |
| Cancer Therapy & Research Center Endowment | Health Services |
Flagship Biosciences, Inc.
Flagship Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Flagship Biosciences, Inc. engages in medical and biological research. It offers drug development support, including target validation and hypothesis generation, exploratory and efficacy endpoints, predictive strategy building and companion diagnostics.The company was founded by G. David Young in 2009 and is headquartered in Broomfield, CO. | Commercial Services |
- Bolsa de valores
- Insiders
- Gary M. Clark
- Experiencia
